Trading of Noveris Health Sciences Securities Halted by BCSC

Vancouver, British Columbia — March 26, 2026 — Leads & Copy — Noveris Health Sciences Inc. has announced that the British Columbia Securities Commission (BCSC) issued an order halting all trading in the company’s securities until April 16, 2026.

The order, dated March 25, 2026, was issued under section 89(1) of the Securities Act (British Columbia). The BCSC cited unexplained and unusual fluctuations in the volume of trading in, or market price, of the company’s shares traded on the CSE as the reason for the order. The full text of the order can be viewed on www.sedarplus.ca.

Noveris Health Sciences also clarified that it did not authorize, commission, or participate in the creation or distribution of an article concerning the company that was circulated by John Michaels on March 19, 2026. The company confirmed that neither it nor its investor relations service provider was aware of the article prior to its publication. They also stated that they have no relationship or affiliation with the individual or entities responsible for its authorship or dissemination.

According to the press release, the company did not provide information, commentary, review, approval, or input of any kind regarding the article. Noveris Health Sciences stated that any statements, claims, or opinions expressed in the article should not be construed as having been reviewed, verified, endorsed, or supported by the company.

The company specifically addressed a statement in the article that said “the company is FDA-registered.” Noveris Health Sciences stated that to the extent “FDA” refers to the U.S. Food and Drug Administration, this statement is inaccurate. The company clarified that it does not have any registrations with the Food and Drug Administration, nor is it actively pursuing any applications for registration for any of its products at this time.

Noveris Health Sciences refers readers to its public disclosure, which it says remains current. The company confirms that it has no material undisclosed information at this time.

Noveris intends to cooperate fully with the BCSC and to work diligently toward satisfying any conditions necessary for the resumption of trading of its common shares on the CSE. The company will provide further information as it becomes available.

Noveris Health Sciences Inc. is a biotechnology company developing medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The company’s core strategy blends advanced technology with an infrastructure for drug discovery and development. Noveris’ dedicated multinational team constantly develops new paths for treatment solutions in areas with considerable unmet needs.

The company collaborates with specialists to speed up the development of medications to provide patients with safer and more effective treatment solutions. Noveris’ approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts and expertise.

Source: Noveris Health Sciences Inc.